Compare Novartis AG (NVS) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Novartis AG trades at $152.64 (market cap $295.37B), while Consumer Discretionary Select Sector SPDR Fund trades at $118.16. The key difference: Novartis AG pays a 3.07% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| NVS | XLY | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | — |
52-Week High | $168.62 | $124.52 |
52-Week Low | $119.31 | $105.64 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
XLY trades at $118.93, down 0.62% today, with a bullish technical signal from moving averages and neutral oscillators. Analyst consensus is unanimously positive with a 100% buy rating. The ETF shows strong technical momentum, though RSI levels indicate potential overbought conditions near-term.
The outlook remains favorable given bullish analyst sentiment and technical trends, but risks include consumer spending sensitivity to inflation and concentrated holdings. Upside potential hinges on sustained discretionary spending, while economic slowdowns pose a threat to performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
